


CCPrior Authorization Review Panel  
MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.  
Policies submitted without this form will not be considered for review.

Plan: AmeriHealth Caritas Pennsylvania & Keystone First	Submission Date: 10/1/25
Policy Number: CCP.1469-07	Effective Date: 10/1/2020 Revision Date: 9/1/2025
Policy Name: Percutaneous arteriovenous fistula creation	
Type of Submission:	Type of Policy:
<input type="checkbox"/> New Policy	<input checked="" type="checkbox"/> Prior Authorization Policy
<input checked="" type="checkbox"/> Revised Policy*	<input type="checkbox"/> Base Policy
<input type="checkbox"/> Annual Review- no revisions	<input checked="" type="checkbox"/> Experimental/Investigational Policy
	<input type="checkbox"/> Statewide PDL
	<input type="checkbox"/> Other:
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any clarifying information for the policy below:</p>	
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:
Manni Sethi, MD, MBA, CHCQM	

# Percutaneous arteriovenous fistula creation

Clinical Policy ID: CCP.1469-07

Recent review date: 9/2025

Next review date: 1/2027

Policy contains: Arteriovenous fistula; Ellipsys; endovascular; everlinQ; hemodialysis; percutaneous; WavelinQ

*Keystone First- CHIP has developed clinical policies to assist with making coverage determinations. Keystone First- CHIP's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Keystone First- CHIP, on a case by case basis, when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Keystone First- CHIP's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Keystone First- CHIP's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Keystone First- CHIP will update its clinical policies as necessary. Keystone First- CHIP's clinical policies are not guarantees of payment.*

## Coverage policy

Percutaneous arteriovenous fistula creation for hemodialysis access is investigational/not clinically proven and, therefore, not medically necessary.

Note: For Medicare Advantage and for Pennsylvania Medical Assistance, percutaneous arteriovenous fistula creation for hemodialysis access may be requested as a program exception and may be reviewed on a case by case basis.

### Limitations

No limitations were identified during the writing of this policy.

### Alternative covered services

- Arteriography.
- Contrast venography.
- Duplex ultrasound.
- Hemodialysis vascular access (arteriovenous graft, central line catheter).
- History and physical examination specific to vascular access selection.
- Nephrology consultation.
- Vein mapping.

## Background

According to the National Institute of Diabetes and Digestive and Kidney Diseases (2024), an estimated 808,000 Americans have end stage renal disease, 68% of whom receive dialysis. Among patients on hemodialysis, the surgically-created arteriovenous fistula is the most common vascular access (Jayroe, 2022).

Ideally, referral for initial vascular access placement should occur approximately three to six months in advance of the anticipated need for dialysis to allow for adequate maturation time. Maturation failure, infection, and venous stenosis or thrombosis after maturation continue to complicate hemodialysis access. Additional procedures and prolonged central venous catheter use may be needed, further increasing the risk of bacteremia, inadequate dialysis, and death (Schmidli, 2018). One administrative study of Medicare claims data found that only 54.7% of surgically created fistula were used within four months of placement (Woodside, 2018).

Vascular surgeons generally prefer the vascular anatomy of the non-dominant over dominant upper extremity, as far distally as possible, to preserve proximal sites for future access. The four preferred sites are radiocephalic or radiobasilic transposition in the forearm, and brachiocephalic or brachioasilic transposition in the upper arm. For optimal placement, duplex ultrasound and vein mapping provide important information on arterial inflow and venous outflow, along with vein diameter and length and proximal vein patency (DeVita, 2020).

To improve arteriovenous creation, maturation, and suitability for dialysis, a minimally invasive endovascular approach has been developed (Jayroe, 2022). Endovascular access minimizes vascular injury at the time of arteriovenous fistula creation and creates a channel between the artery and vein with an angle approaching zero degrees. Endovascular placement can be performed by an interventionalist, which may reduce the delays associated with surgical scheduling. The procedure can be done with regional or local anesthesia without the need for a surgical incision, general anesthesia, or additional interventions.

The U.S. Food and Drug Administration has cleared percutaneous catheters for the creation of an arteriovenous fistula for hemodialysis access as Class II devices. The Ellipsys® Vascular Access System (Avenu Medical Inc., San Juan Capistrano, California) applies direct current heat to create an elliptical anastomosis between the proximal radial artery and perforating vein via a retrograde venous access approach (U.S. Food and Drug Administration, 2018). The modified and predicate versions are indicated for patients with a minimum vessel diameter of 2.0 mm and less than 1.5 mm of separation between the artery and vein at the fistula creation. The most recent generation includes a procedural step of balloon dilation immediately following fistula creation. The procedure is carried out under ultrasound guidance. Approval was based on the results of the Ellipsys Vascular Access System Clinical Trial (ClinicalTrials.gov identifier: NCT02363972; Hull, 2018).

Formerly called everlinQ®, the WavelinQ™ Plus EndoAVF System and its predicate WavelinQ™ 4-French EndoAVF version (C.R. Bard, Inc., Tempe, Arizona) employ two magnetized catheters to cannulate both the brachial vein and brachial artery and then advance into the ulnar vein and artery (U.S. Food and Drug Administration, 2019a, 2019b). The device is indicated for the creation of an arteriovenous fistula using concomitant ulnar artery and ulnar vein or concomitant radial artery and radial vein in patients with minimum artery and vein diameters of 2.0 mm at the fistula creation site who have chronic kidney disease and need hemodialysis. Approval was based on performance data from three sources: the EverlinQ Endovascular Access Systems Enhancements Study; ClinicalTrials.gov identifiers NCT03708770 and NCT03708562; and a European Union post-market study.

## Findings

### Guidelines

No current guidelines have addressed the endovascular approach in vascular access techniques for hemodialysis, including the European Society for Vascular Surgery (Schmidli, 2018).

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guideline recommended more prospective research to determine whether endovascular fistula creation can result in a clinically durable and cost effective arteriovenous access compared with traditional surgical arteriovenous access creation and maintenance (Lok, 2020).

### Evidence review

We included five systematic reviews and meta-analyses (Bontinis, 2023; Malik, 2021; Shimamura, 2022; Sun, 2022; Yan Wee, 2020). The evidence evaluated the safety and efficacy of endovascular arteriovenous fistula creation and reported on technical success, maturation rates at different follow-up intervals, patency, and procedure-related complications. There was indirect evidence comparing the outcomes of the endovascular approach to the standard surgical approach, but the number of prospective studies representing currently available percutaneous catheters was limited, and studies lacked randomization.

The results suggest endovascular arteriovenous fistula creation is associated with high short-term rates of technical success, maturation, and patency, a low risk of procedure-related complications, and lower associated first-year costs compared with a surgically created arteriovenous fistula. The endovascular approach potentially offers patients with suitable anatomy a less invasive option and leaves open the option of proximal arm placement for secondary arteriovenous access. Nonetheless, given the limited direct comparative analyses with surgical arteriovenous fistula creation and insufficient long-term data, the superiority of an endovascular approach cannot be established at present.

A systematic review/meta-analysis of 18 studies ( $n = 1,863$ ) compared percutaneous endovascular arteriovenous fistula creation (WavelinQ and Ellipsys) with surgical arteriovenous fistula. No significant differences were observed in primary patency, secondary patency, functional cannulation, and abandonment rates. Patients with percutaneous procedures had a decreased risk of subclavian steal syndrome and wound infection. However, one in three WavelinQ procedures resulted in abandonment (Bontinis, 2023).

Similarly, other systematic reviews and meta-analyses found no significant differences between percutaneous endovascular and surgical techniques with respect to rates of procedural success, maturation, and complications (Malik, 2021; Shimamura, 2022; Sun, 2022; Yan Wee, 2020). Malik (2021) did find significant differences in procedural time, number of interventions needed to maintain patency, and primary patency rate between the two cohorts (all  $P < .001$ ).

Recent results from retrospective analyses suggest both surgical and endovascular access types can provide hemodialysis access, but several factors may influence their relative safety and efficacy. These factors include the technical characteristics of each access type (e.g., Ellipsys versus WaveLinQ or different generations of WaveLinQ), use of drug-coated balloon angioplasty during secondary percutaneous transluminal angioplasty, and choice of outcome measure (e.g., immediate procedural outcomes versus long term functionality) (Hogan, 2024; Shahverdyan, 2024, 2025).

Wasse (2019) highlighted several unanswered questions related to its suitability and durability for dialysis that need to be addressed before widespread use:

- What adjustments to blood pump speed and dialysis time may be required to achieve a prescribed dialysis dose?
- Which secondary interventions will be needed to maintain arteriovenous fistula function long term?
- How would surgical transposition affect arteriovenous fistula function?
- What impact would an endovascular approach have on subsequent arteriovenous access creation?
- What education and training would be required to support widespread use?

In 2024, we updated the references. No policy changes are warranted.

In 2025, we updated the references and reorganized the findings section. No policy changes are warranted.

## References

On July 9, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “arteriovenous fistula” (MeSH), “endovascular procedures” (MeSH), “arteriovenous fistula creation,” “endoarteriovenous fistula,” and “ellipsys.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Bontinis A, Bontinis V, Koutsoumpelis A, et al. A systematic review aggregated data and individual participant data meta-analysis of percutaneous endovascular arteriovenous fistula. *J Vasc Surg*. 2023;77(4):1252-1261.e3. Doi: 10.1016/j.jvs.2022.10.039.

DeVita MV, Khine SK, Shivarov H. Novel approaches to arteriovenous access creation, maturation, suitability, and durability for dialysis. *Kidney Int Rep*. 2020;5(6):769-778. Doi: 10.1016/j.ekir.2020.02.1024.

Hogan D, Otoy D, Lavingia K, Amendola M. What is the MAUDE database telling us about 510(k) authorization? Evaluation of two generations of endovascular arteriovenous fistula devices. *Ann Vasc Surg*. 2024;106:394-399. Doi: 10.1016/j.avsg.2024.03.029.

Hull JE, Jennings WC, Cooper RI, et al. The pivotal multicenter trial of ultrasound-guided percutaneous arteriovenous fistula creation for hemodialysis access. *J Vasc Interv Radiol*. 2018;29(2):149-158.e145. Doi: 10.1016/j.jvir.2017.10.015.

Jayroe H, Foley K. Arteriovenous fistula. *StatPearls [internet]*. Treasure Island (FL): StatPearls Publishing. 2025 Jan-. <https://www.ncbi.nlm.nih.gov/books/NBK559213/>. Updated November 21, 2022.

Lok CE, Huber TS, Lee T, et al. KDOQI clinical practice guideline for vascular access: 2019 update. *Am J Kidney Dis*. 2020;75(4 Suppl 2):S1-S164. Doi: 10.1053/j.ajkd.2019.12.001.

Malik MH, Mohammed M, Kallmes DF, Misra S. Endovascular versus surgical arteriovenous fistulas: A systematic review and meta-analysis. *Kidney Med*. 2021;4(3):100406. Doi: 10.1016/j.xkme.2021.100406.

National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States. <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease#:~:text=Nearly%20808%2C000%20people%20in%20the,to%20develop%20ESKD%20than%20wome>n. Last reviewed September 2024.

Schmidli J, Widmer MK, Basile C, et al. Editor's choice – Vascular access: 2018 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg*. 2018;55(6):757-818. Doi: 10.1016/j.ejvs.2018.02.001.

Shahverdyan R, Lessne ML, Mehta TI. Comparison of outcomes of drug-coated balloons versus plain balloons in secondary interventions on percutaneous arteriovenous fistulae. *J Vasc Interv Radiol*. 2024;35(8):1176-1186.e1. Doi: 10.1016/j.jvir.2024.04.014.

Shahverdyan R, Mehta TI, Inston N, Konner K, Vartanian S. Long term results of a comparative study of percutaneous and surgically created proximal forearm arteriovenous fistulae. *Eur J Vasc Endovasc Surg*. 2025;69(5):757-765. Doi: 10.1016/j.ejvs.2025.01.020.

Shimamura S, Kuniyoshi Y, Ueta H, Miyauchi T, Yamazaki H, Tsujimoto Y. A comparison between the efficacy and safety of endovascular arteriovenous fistula creation and surgical fistula creation: A systematic review and meta-analysis. *Cureus*. 2022;14(5):e25091. Doi: 10.7759/cureus.25091.

Sun J-B, Liu C-C, Shen X, Chen Q, Xu C-L, Cui T-L. Percutaneous endovascular arteriovenous fistula: A systematic review and meta-analysis. *Front Cardiovasc Med*. 2022;9:978285. Doi: 10.3389/fcvm.2022.978285.

U.S. Food and Drug Administration. 510(k) submission letter K182796. Trade/Device Name: WavelinQ 4F EndoAVF System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf18/K182796.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf18/K182796.pdf). Decision date February 6, 2019. (a)

U.S. Food and Drug Administration. 510(k) submission letter K192239. Trade/Device Name: WavelinQ Plus EndoAVF System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K192239.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192239.pdf). Decision date October 17, 2019. (b)

U.S. Food and Drug Administration. De novo classification request for Ellipsys® vascular access system. Dated January 10, 2017. [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN170004.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170004.pdf). Decision date June 22, 2018.

Wasse H. Place of percutaneous fistula devices in contemporary management of vascular access. *Clin J Am Soc Nephrol*. 2019;14(6):938-940. Doi: 10.2215/cjn.00980119.

Woodside KJ, Bell S, Mukhopadhyay P, et al. Arteriovenous fistula maturation in prevalent hemodialysis patients in the United States: A national study. *Am J Kidney Dis*. 2018;71(6):793-801. Doi: 10.1053/j.ajkd.2017.11.020.

Yan Wee IJ, Yap HY, Tang TY, Chong TT. A systematic review, meta-analysis, and meta-regression of the efficacy and safety of endovascular arteriovenous fistula creation. *J Vasc Surg*. 2020;71(1):309-317.e305. Doi: 10.1016/j.jvs.2019.07.057.

## Policy updates

9/2020: initial review date and clinical policy effective date: 10/2020

9/2021: policy retired

9/2023: policy re-introduced, references updated.

9/2024: policy references updated.

9/2025: Policy references updated.